Background and Purpose-The combination of risk factors known as the metabolic syndrome is receiving increased attention, but prospective data on the syndrome's association with ischemic cerebrovascular events are scarce. We explored the relation of metabolic syndrome versus frank diabetes with first-ever ischemic stroke or transient ischemic attack (TIA) in a large cohort of patients with atherosclerotic cardiovascular disease. Methods-Patients with coronary heart disease, screened for a clinical trial, underwent an extensive medical evaluation and follow-up for cerebrovascular disease over 4.8 to 8.1 years. National Cholesterol Education Program Adult Treatment Panel III criteria were used to define the metabolic syndrome, with body mass index substituted for waist circumference.
T he term "metabolic syndrome" has been proposed to define a cluster of several risk factors for cardiovascular disease. 1, 2 The National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) report 3 formulated their definition of metabolic syndrome for clinical use. It is based on the presence of Ն3 of the following components: high fasting glucose, high blood pressure, low highdensity lipoprotein cholesterol, high triglycerides, and abdominal obesity. Prospective studies have shown that the presence of the metabolic syndrome is associated with a significant increased risk of morbidity and mortality from cardiovascular disease. 4 -11 Although the metabolic syndrome is often considered a prediabetic condition and diabetes is a major risk factor for ischemic stroke, the association of the metabolic syndrome without diabetes with incident ischemic cerebrovascular events has not been studied in depth. The aim of the current study is to assess the prevalence of the metabolic syndrome in a large cohort of patients with atherosclerotic cardiovascular diseases and to explore the relation of the metabolic syndrome with first-ever ischemic cerebrovascular events.
Materials and Methods

Patients
The initial study sample comprised 15 524 patients with documented coronary heart disease (CHD) screened in 18 centers for inclusion in a placebo-controlled secondary prevention randomized clinical trial, assessing the effect of bezafibrate on recurrent events and mortality (the BIP randomized clinical trial). 12 In this trial, bezafibrate retard users and nonusers exhibited comparable rates of incident stroke. We deduced that this justifies including the bezafibrate retard users with others in the current analysis. Patients were screened between February 1990 and October 1992. Patients aged 45 to 74 years with diagnosis of CHD were eligible for screening if they had evidence of myocardial infarction occurring Ն6 months but Յ5 years before enrollment, or coronary insufficiency observed either at rest or during effort, as manifested by typical pain and dynamic electrocardiographic changes, or both. Myocardial infarction was defined by standard clinical definition at the time of the screening. Coronary insufficiency episodes must have occurred between 6 months and 2 years before enrollment. During the first visit, records were obtained on the candidate's medical history, conventional risk factors, and medication used, and a complete physical examination was performed. Patients with a history of previous stroke or transient ischemic attack (TIA) were excluded to assess the risk of first-ever stroke. For 805 patients who underwent the baseline examinations, the long-term fate is not known, because they were neither citizens nor permanent residents and were therefore excluded from analyses. Additional 435 patients were excluded because of diagnoses of subarachnoid hemorrhage or subdural hematoma or history of a previous cerebrovascular event. The final study sample therefore comprised 14 284 patients.
Laboratory Examination
Laboratory measurements were performed in a central laboratory (Physiological and Hygiene Laboratory, Wolfson Medical Center, Holon, Israel). All analyses were performed with a BoehringerHitachi 704 random-access analyzer with Boehringer diagnostic kits. Accuracy and precision were under periodic surveillance by the Centers for Disease Control and Prevention Service in Atlanta, Georgia. Blood samples were taken after 12 hours of fasting. Glucose concentrations were determined using an enzymatic colometric method (GOD/PAP). Cholesterol was determined by the CHOD-PAP method.
Definition of Diabetes and Metabolic Syndrome
According to the 1999 WHO Consultation recommendations for the diagnosis of diabetes, patients with previously diagnosed diabetes (reported history of diabetes diagnosed by a physician or patients who were taking antidiabetic medication) or with a fasting plasma glucose level Ͼ125 mg/dL (Ն7.0 mmol/L) were considered as having diabetes. Patients were considered as having the metabolic syndrome if they had Ն3 of the following components, based on modification of the NCEP/ATP III: hypertension defined as a systolic blood pressure Ն130 mm Hg and/or a diastolic blood pressure Ն85 mm Hg and, by history of hypertension, raised plasma triglycerides (Ն150 mg/dL [1.7 mmol/L]), low high-density lipoprotein cholesterol levels (Ͻ40 mg/dL in men and Ͻ50 mg/dL in women), and impaired fasting glucose defined as fasting plasma glucose concentration Ն110 mg/dL (6.1 mmol/L), but less than the criteria for diabetes of Ͼ125 mg/dL (Ն7.0 mmol/L). For a definition of obesity, we used a body mass index Ն30 kg/m 2 instead of waist circumference because the latter was not measured in our cohort.
Assessment of Cerebrovascular Disease
We obtained computerized data files of hospitalizations with a diagnosis of cerebrovascular disease (ICD-9 codes 430 to 438 or code 38.1-endarterectomy surgery) during 1997 to 1998 4.8 to 8.1 years after the screening process that took place between 1990 and 1992. We matched the patients against a registry of all hospitals but one and the Clalit Health Services (insuring Ͼ60% of population) participating in the screening process. Patients were identified and attainable medical records and hospital discharge summaries were systematically reviewed. Data were collected on history, findings on neurological examination, brain CT, and ancillary examinations, as available, to verify the diagnosis and to determine stroke type. Stroke was defined according to World Health Organization (WHO) criteria. Ischemic stroke and intracerebral hemorrhage were differentiated by the results of brain CT performed at the acute stage. Ischemic stroke was diagnosed if the patient had an appropriate clinical event and had a brain CT that showed a compatible low-density lesion or was normal, or had findings compatible with hemorrhagic conversion of a cerebral infarct. Events resolving completely within Ͻ24 hours were diagnosed as TIA. Of 1111 cases considered having any incident ischemic cerebrovascular disease by ICD 9 codes, in 614 patients the diagnosis of ischemic stroke or TIA was verified after review of medical records, and these cases were regarded as the endpoint for this analysis. Remaining patients were admitted for carotid endarterectomy surgery for asymptomatic disease, or medical records were not available for review, or brain CT was not performed, so that the type of cerebrovascular disease could not be determined.
Statistical Analysis
ANOVA and the 2 tests were performed for the baseline characteristics and major risk factors differences between the 3 groups, including components of the metabolic syndrome. Age-adjusted rates of ischemic stroke or TIA incidence by the number of components of the metabolic syndrome were calculated. Adjusted odds ratios (ORs) for the incidence of ischemic stroke or TIA and 95% confidence intervals (CIs) were calculated from multivariate logistic regression for each component of metabolic syndrome. To estimate the risk prediction by the number of these components and the independent contribution of the metabolic syndrome, predicted ischemic stroke or TIA rates were calculated by the logistic regression model, adjusting for age, sex, current smoking, past myocardial infarction, peripheral vascular disease, lipid-modifying drugs, lowdensity lipoprotein cholesterol, and antiplatelets and antihypertensive medications. The Hosmer-Lemeshow goodness-of-fit test was performed to assess overall model fit. Time-to-event measurements were calculated as time from screening to the occurrence of the events (fatal and nonfatal) or time of screening to death from other causes, or time to the end of follow-up. The log rank test was calculated to compare survival curves. Data were analyzed with the SPSS version 12.0 kit.
Results
The study sample comprised 14 284 patients, of which 7203 (50%) fulfilled the criteria for either the metabolic syndrome or diabetes. Criteria for the metabolic syndrome without diabetes were met by 3703 (26%) patients and for diabetes by an additional 3500 (25%) patients. Changing the criteria for impaired fasting glucose to plasma glucose concentration Ͼ100 mg/dL would have increased the rate of the metabolic syndrome without diabetes to 31% and of the metabolic syndrome or diabetes to 56%.
Comparisons of baseline clinical, demographic, and metabolic characteristics of patients with metabolic syndrome, diabetes, or neither are given in Table 1. Table 2 presents the rates and ORs for incident ischemic stroke or TIA by the different components of metabolic syndrome among patients without diabetes. Each of the components individually was a significant predictor for ischemic stroke or TIA. The strongest predictors were impaired fasting glucose and hypertension. As compared with patients without any component of the metabolic syndrome, the adjusted ORs for incident ischemic stroke or TIA among patients without diabetes increased from 1.27 for one component to 1.93 for 3 components and as high as 2.36 for 4 or 5 components (Table  3) . Trends were more pronounced in women, as depicted in Figure 1 .
Adjusting for stroke risk factors, patients with the metabolic syndrome without diabetes exhibited a 1.49-fold in-creased odds of ischemic stroke or TIA (95% CI, 1.20 to 1.84), whereas those with frank diabetes had a 2.29-fold increased odds (95% CI, 1.88 to 2.78). The relative odds of ischemic stroke or TIA associated with presence of the metabolic syndrome per se were 1.39 (95% CI, 1.10 to 1.77) in men but 2.10 (95% CI, 1.26 to 3.51) in women (Table 4) . Changing the criteria for impaired fasting glucose to plasma glucose concentration Ͼ100 mg/dL, the ORs remained sig- Figure 2 . Compared with nondiabetic patients without the metabolic syndrome, adjusted ORs were 1.45 (95% CI, 1.15 to 1.84) for diabetic patients with 3 components of the metabolic syndrome, 1.69 (95% CI, 1.20 to 2.37) for nondiabetic patients with Ͼ3 components of the metabolic syndrome, 1.95 (95% CI, 1.42 to 2.68) for diabetic patients with Ͻ3 components of the metabolic syndrome, and 2.47 (95% CI, 2.00 to 3.05) for diabetic patients with Ն3 components of the metabolic syndrome.
Discussion
In the current analysis of Ͼ14 000 CHD patients we found a significant increase in the risk of ischemic stroke or TIA in the presence of the metabolic syndrome without diabetes. The presence of the metabolic syndrome per se was associated with a 1.5-fold higher risk versus Ͼ2-fold higher risk associated with the presence of diabetes. This implies that identification of the metabolic syndrome in this high-risk category of patients, even before the occurrence of diabetes, could identify patients at a greater risk of ischemic cerebrovascular event. Although both men and women with the metabolic syndrome were at increased risk of ischemic stroke, the latter was more pronounced in women (ORϭ2.10) than in men (ORϭ1.39), in agreement with increased relative cardiovascular risk among prediabetic women in comparison to men. 13 Over half the patients in our cohort had either the metabolic syndrome or diabetes (26% with metabolic syndrome without diabetes and 25% diabetic). This high prevalence is comparable to other cohorts of patients with manifest atherosclerotic vascular disease 14 and higher than the prevalence (26%) in a cohort representative of the adult US population. 11 The newly recommended criteria for impaired fasting glucose is Ն100 mg/dL, 15 and such fasting glucose concentrations identify patients at increased risk for ischemic stroke. 16 Changing the criteria for impaired fasting glucose to Ն100 mg/dL increases the prevalence of the metabolic syndrome without diabetes to nearly one-third of the cohort but does not change materially the ORs for ischemic stroke or TIA.
Several studies have demonstrated that the presence of metabolic syndrome is associated with an increased risk of cardiovascular disease, 4 -11 but data on the association with ischemic stroke is scarce. In a cross-sectional study from the Third National Health and Nutrition Examination survey, the metabolic syndrome was significantly associated with selfreported myocardial infarction and stroke. 17 The presence of the metabolic syndrome was associated with increased cardiovascular, as well as cerebrovascular, mortality. 6, 11 In a prospective study of subjects with hypertension without cardiovascular diseases, the metabolic syndrome was an independent predictor for both cardiovascular and cerebrovascular disease (hazard ratioϭ2.1). 18 Our current study extends this association, finding an increased risk of ischemic stroke or TIA in patients with atherosclerotic cardiovascular disease.
The metabolic syndrome comprises a cluster of abnormalities that occur as a result of perturbations in multiple metabolic pathways, leading to hyperinsulinemia, insulin resistance hyperglycemia, atherogenic dyslipidemia, and hypertension. The root causes of the syndrome appear to be multiple and include obesity (especially abdominal obesity), physical inactivity, insulin resistance, aging, and genetics. 19 Several studies have also shown that the metabolic syndrome is a proinflammatory condition. 20, 21 The incremental increase in ischemic stroke or TIA risk with increasing number of components constituting the metabolic syndrome supports the requirement of the NCEP/ATP III of at least 3 components for establishing the diagnosis of metabolic syndrome 3 and demonstrates the further increase in risk for those with 4 or 5 components of the syndrome. Comparable findings were observed for cardiovascular disease with Ͼ5-fold increased risk in patients with Ն4 components compared with those with Յ1 component during a 5-year observational period. 10 Increment in the number of components constituting the metabolic syndrome was also associated in a cross-sectional study with an increase in surrogate markers of vascular damage in patients with manifest atherosclerotic vascular disease. 22 Our study has several limitations. First, information concerning potential spontaneous or therapy-induced changes in the components of metabolic syndrome during follow-up was not available. We have controlled for the use of lipidmodifying drugs at baseline. It should be noted, however, that statin therapy was gradually introduced only in the latter part of the follow-up period. Second, data on the incidence of ischemic stroke or TIA were obtained through medical records from participating hospitals. Patients with minor strokes not admitted to hospital and those who had been re-admitted to a nonparticipating hospital would have been missed. Incidence rates, however, were comparable in patients followed-up routinely as part of a randomized clinical trial 12 and patients for whom data were obtained through medical records. Complete medical records were not available in all cases, but comparable findings were observed also for the endpoint of all ischemic cerebrovascular disease (nϭ1111) defined by ICD codes. Finally, our findings involve a cohort of patients with manifest atherosclerotic disease, and these results should not be generalized to other populations.
In the current study, we have found that components of metabolic syndrome are highly prevalent in patients with CHD. The components with strongest relation with ischemic stroke or TIA are hypertension and impaired fasting glucose. Although the metabolic syndrome without diabetes is a less potent risk factor for ischemic stroke or TIA than diabetes, it occurs more often than frank diabetes and its prevalence is reported to be continuously growing, making it a pertinent clinical entity. 19 Further investigation is required in other cohorts to determine whether the metabolic syndrome increases the risk of ischemic stroke more in women than in men, as in the present cohort. Attention is required to identify the metabolic syndrome even in patients with pre-existing atherothrombotic disease. More intensive lifestyle changes and management protocols may be required in these patients for controlling the components of the syndrome, with the aim of preventing not only type II diabetes and cardiovascular disease but also ischemic cerebrovascular events. 
